| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | IN; LHR; MC56; MDU2; MDU3; MIC4; Pgp1; CDW44; CSPG8; HCELL; HUTCH-I; ECMR-III |
| WB Predicted band size | 82 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CD44 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CD44抗体的3篇参考文献的简要信息(文献标题、作者及摘要概括)：
---
1. **文献名称**：*CD44: From adhesion molecules to signalling regulators*
**作者**：Ponta, H., Sherman, L., & Herrlich, P.A.
**摘要**：该综述探讨了CD44作为细胞表面黏附分子的多功能性，重点分析了其与透明质酸等配体的相互作用，以及CD44抗体在抑制肿瘤转移和炎症反应中的潜在应用机制。
---
2. **文献名称**：*Targeting CD44-expressing cells with monoclonal antibodies: A novel therapeutic strategy for cancer treatment*
**作者**：Goodison, S., et al.
**摘要**：研究验证了抗CD44单克隆抗体(如H90和IM7)通过阻断CD44与微环境配体的结合，抑制肿瘤干细胞存活和转移的疗效，并探讨了其在乳腺癌和结直肠癌中的临床前数据。
---
3. **文献名称**：*CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of acute myeloid leukemia*
**作者**：Jin, L., et al.
**摘要**：该研究开发了CD44抗体偶联的纳米颗粒，用于急性髓系白血病(AML)的靶向治疗和成像，证明其可特异性结合CD44高表达的AML细胞并增强化疗药物递送效率。
---
4. **文献名称**：*Structural basis of CD44 homodimerization and antibody recognition*
**作者**：Banerji, S., et al.
**摘要**：通过X射线晶体学解析了CD44胞外域的结构，揭示了其同源二聚化机制，并阐明了特定抗CD44抗体(如S5)的结合表位，为抗体药物设计提供结构生物学依据。
---
以上文献涵盖CD44抗体的功能机制、治疗应用及结构研究，可为进一步研究提供方向参考。如需具体出版信息或DOI，可补充说明。
CD44 antibodies are tools designed to target CD44. a widely expressed transmembrane glycoprotein involved in cell-cell adhesion, cell-matrix interactions, and cellular signaling. CD44 serves as a primary receptor for hyaluronic acid (HA) and interacts with other ligands like osteopontin, collagens, and growth factors. It exists as multiple isoforms generated by alternative splicing, with the standard isoform (CD44s) and variant isoforms (CD44v) exhibiting distinct roles in physiological and pathological processes. CD44 is implicated in cancer progression, inflammation, and stem cell maintenance, making it a focus of research and therapeutic development.
In cancer biology, CD44 is often linked to tumor initiation, metastasis, and therapy resistance, particularly as a marker for cancer stem cells (CSCs) in malignancies like breast, colorectal, and pancreatic cancers. CD44 antibodies, such as clones Hermes-3. IM7. and S5-6. are widely used in research to study its expression, function, and downstream pathways. These antibodies enable applications like flow cytometry, immunohistochemistry, and functional blocking experiments. Clinically, CD44-targeting antibodies have been explored in diagnostics and therapies, including antibody-drug conjugates (ADCs) and immune-based approaches to disrupt CSC niches or inhibit pro-tumorigenic signaling.
Despite promise, challenges remain due to CD44's structural complexity, context-dependent roles, and redundancy in signaling pathways. Ongoing efforts aim to optimize isoform-specific antibodies and combinatorial strategies to enhance therapeutic efficacy.
×
